Arrowhead Reports Phase 3 Plozasiran Data Reducing Pancreatitis
Pasadena, Calif. – August 30, 2026 Arrowhead Pharmaceuticals presented detailed Phase 3 SHASTA-3 and SHASTA-4 data showing that plozasiran...
Acute Pancreatitis
Advertisement
Ionis and AstraZeneca Showcase Cardiovascular Pipeline Progress with New Data at ESC Congress 2026
CARLSBAD, California, August 20, 2026 Ionis Pharmaceuticals, Inc. announced that new clinical data supporting its severe hypertriglyceridemia (sHTG) treatment...
CalciMedica Advances Auxora and CM5480 in Pulmonary Hypertension
LA JOLLA, Calif., August 11, 2026 CalciMedica, Inc. reported its second-quarter 2026 financial results and provided updates across its...
CalciMedica Aligns With FDA on Auxora Phase 2b Trial
LA JOLLA, Calif., July 29, 2026 CalciMedica, Inc. has announced a significant regulatory milestone after reaching alignment with the...
Arrowhead Pharmaceuticals Reports Positive Phase 3 Plozasiran Results
PASADENA, Calif., July 22, 2026 Arrowhead Pharmaceuticals announced positive topline results from its pivotal Phase 3 SHASTA-3 and SHASTA-4...
Advertisements
Ionis Wins FDA Approval for TRYNGOLZA in Severe Hypertriglyceridemia
CARLSBAD, Calif., June 24, 2026 Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA®...
Advertisement
